Cargando…
Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
BACKGROUND: Osteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical tec...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567946/ https://www.ncbi.nlm.nih.gov/pubmed/33088699 http://dx.doi.org/10.1016/j.jbo.2020.100319 |
_version_ | 1783596430556921856 |
---|---|
author | Papakonstantinou, Evgenia Stamatopoulos, Alexandros I Athanasiadis, Dimitrios Kenanidis, Efstathios Potoupnis, Michael Haidich, Anna-Bettina Tsiridis, Eleftherios |
author_facet | Papakonstantinou, Evgenia Stamatopoulos, Alexandros I Athanasiadis, Dimitrios Kenanidis, Efstathios Potoupnis, Michael Haidich, Anna-Bettina Tsiridis, Eleftherios |
author_sort | Papakonstantinou, Evgenia |
collection | PubMed |
description | BACKGROUND: Osteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical techniques; however, controversy still exists concerning the best surgical method. Our meta-analysis compared the effectiveness of LSS and amputation combined with neoadjuvant chemotherapy in patients with limb osteosarcoma, in terms of 5-year overall survival (OS), 5-year disease-free survival (DFS) and local recurrence rate. METHODS: Following the established methodology of PRISMA guidelines, a literature search was conducted in PubMed, Cochrane, Google Scholar from 1975 until January 2020. Two independent reviewers evaluated the study quality based on the Newcastle-Ottawa scale. Odds ratio and 95% confidence interval of the OS, DFS and local recurrence rate were calculated. RESULTS: Thirteen studies were finally included with a total of 2884 patients; 1986 patients undergone LSS and 898 amputations. Five-year overall survival was almost 2-fold in patients treated with LSS than those treated with amputation (OR: 1.99; 95% CI: 1.35–2.93; I(2) = 74%, p < 0.001). No difference was found in 5-year DFS between LSS patients and amputees (OR: 1.24; 95% CI: 0.55–2.79; I(2) = 67%, p = 0.01). The odds of local recurrence was numerically higher in LSS compared to amputation but not statistically significant (OR: 2.29; 95% CI: 0.95–5.53; I(2) = 47%, p = 0.05). However, the included studies did not clearly define differences in the stages of patients of the two groups. CONCLUSION: Our study demonstrated that in patients with limb osteosarcoma treated with neoadjuvant chemotherapy, LSS is associated with a higher 5-year overall survival and the odds of local recurrence may be increased but these results should be interpreted with caution due to high heterogeneity. |
format | Online Article Text |
id | pubmed-7567946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75679462020-10-20 Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis Papakonstantinou, Evgenia Stamatopoulos, Alexandros I Athanasiadis, Dimitrios Kenanidis, Efstathios Potoupnis, Michael Haidich, Anna-Bettina Tsiridis, Eleftherios J Bone Oncol Review Article BACKGROUND: Osteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical techniques; however, controversy still exists concerning the best surgical method. Our meta-analysis compared the effectiveness of LSS and amputation combined with neoadjuvant chemotherapy in patients with limb osteosarcoma, in terms of 5-year overall survival (OS), 5-year disease-free survival (DFS) and local recurrence rate. METHODS: Following the established methodology of PRISMA guidelines, a literature search was conducted in PubMed, Cochrane, Google Scholar from 1975 until January 2020. Two independent reviewers evaluated the study quality based on the Newcastle-Ottawa scale. Odds ratio and 95% confidence interval of the OS, DFS and local recurrence rate were calculated. RESULTS: Thirteen studies were finally included with a total of 2884 patients; 1986 patients undergone LSS and 898 amputations. Five-year overall survival was almost 2-fold in patients treated with LSS than those treated with amputation (OR: 1.99; 95% CI: 1.35–2.93; I(2) = 74%, p < 0.001). No difference was found in 5-year DFS between LSS patients and amputees (OR: 1.24; 95% CI: 0.55–2.79; I(2) = 67%, p = 0.01). The odds of local recurrence was numerically higher in LSS compared to amputation but not statistically significant (OR: 2.29; 95% CI: 0.95–5.53; I(2) = 47%, p = 0.05). However, the included studies did not clearly define differences in the stages of patients of the two groups. CONCLUSION: Our study demonstrated that in patients with limb osteosarcoma treated with neoadjuvant chemotherapy, LSS is associated with a higher 5-year overall survival and the odds of local recurrence may be increased but these results should be interpreted with caution due to high heterogeneity. Elsevier 2020-09-15 /pmc/articles/PMC7567946/ /pubmed/33088699 http://dx.doi.org/10.1016/j.jbo.2020.100319 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Article Papakonstantinou, Evgenia Stamatopoulos, Alexandros I Athanasiadis, Dimitrios Kenanidis, Efstathios Potoupnis, Michael Haidich, Anna-Bettina Tsiridis, Eleftherios Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis |
title | Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis |
title_full | Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis |
title_fullStr | Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis |
title_full_unstemmed | Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis |
title_short | Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis |
title_sort | limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. a systematic review and meta-analysis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567946/ https://www.ncbi.nlm.nih.gov/pubmed/33088699 http://dx.doi.org/10.1016/j.jbo.2020.100319 |
work_keys_str_mv | AT papakonstantinouevgenia limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis AT stamatopoulosalexandros limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis AT iathanasiadisdimitrios limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis AT kenanidisefstathios limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis AT potoupnismichael limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis AT haidichannabettina limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis AT tsiridiseleftherios limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis |